Insomnia + Mirtazapine
Mirtazapine is known to produce insomnia, a physical effect. A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characterized by a racing mind, heightened alertness, and a frustrating disconnect between bodily fatigue and mental wakefulness. This effect can persist for hours beyond the primary duration of a substance, significantly extending the total experience timeline.
About Insomnia
Insomnia induced by psychoactive substances presents as a state where the body may feel exhausted yet the mind refuses to power down. Lying in bed, one experiences a paradoxical combination of physical tiredness—heavy limbs, sore muscles, drooping eyelids—paired with a brain that continues to fire rapidly, cycling through thoughts, replaying experiences, or simply maintaining an irritating baseline alertness that prevents the transition into sleep. The eyes close but consciousness remains stubbornly active, sometimes accompanied by residual visual disturbances, hypnagogic imagery that startles one awake, or a restless inability to find a comfortable position.
The severity follows a clear dose-dependent pattern. At lower doses of stimulating substances, sleep onset may be delayed by 30-60 minutes—an annoyance but manageable. At moderate doses, several hours of wakefulness beyond one's normal bedtime is typical, often accompanied by frustration and physical discomfort. At high doses, particularly with long-acting stimulants or psychedelics, complete inability to sleep for 8-16+ hours after the desired bedtime is possible, leading to significant next-day impairment, emotional instability, and cognitive dysfunction.
Several subtypes of substance-induced insomnia exist. Stimulant insomnia is characterized by mental and physical alertness—the person simply does not feel tired despite knowing they should sleep. Psychedelic insomnia involves a mind that is too visually and conceptually active to settle, often with lingering open-eye or closed-eye imagery. Post-empathogen insomnia combines residual stimulation with emotional processing that keeps consciousness engaged. Withdrawal insomnia, seen after discontinuation of GABAergics or opioids, involves a rebound hyperexcitability that produces fragmented, unsatisfying sleep with frequent awakenings.
Pharmacologically, substance-induced insomnia arises primarily through disruption of the sleep-wake cycle regulated by the suprachiasmatic nucleus and associated neurotransmitter systems. Dopaminergic and noradrenergic stimulants directly oppose the adenosine-mediated sleep drive and maintain cortical arousal. Serotonergic psychedelics disrupt the thalamic gating mechanisms necessary for sleep onset and suppress REM sleep architecture. Caffeine directly antagonizes adenosine receptors. Disruption of GABAergic inhibitory tone, whether through direct stimulation or withdrawal from depressants, prevents the cortical deactivation required for sleep initiation.
This effect is most commonly produced by stimulants (amphetamines, cocaine, MDMA, modafinil, caffeine), psychedelics (LSD is particularly notorious due to its 8-12+ hour duration), and certain nootropics. It also occurs during withdrawal from sedative-hypnotics, benzodiazepines, alcohol, and opioids. Even cannabis cessation after chronic use can trigger rebound insomnia lasting days to weeks.
From a harm reduction perspective, insomnia should be anticipated and planned for when using long-acting substances. Timing dosing to allow sufficient hours before required sleep is essential. Melatonin, magnesium, and calming herbal teas may assist sleep onset. Benzodiazepines and other sedatives are sometimes used as "landing gear" but carry their own risks including dependence and respiratory depression when combined with other depressants. Prolonged sleep deprivation from repeated dosing significantly increases the risk of psychosis, accidents, and immune suppression.